EP0550516A4 - - Google Patents

Info

Publication number
EP0550516A4
EP0550516A4 EP19910916608 EP91916608A EP0550516A4 EP 0550516 A4 EP0550516 A4 EP 0550516A4 EP 19910916608 EP19910916608 EP 19910916608 EP 91916608 A EP91916608 A EP 91916608A EP 0550516 A4 EP0550516 A4 EP 0550516A4
Authority
EP
European Patent Office
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910916608
Other versions
EP0550516A1 (en
Inventor
Franco Celada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospital for Joint Diseases
Original Assignee
Hospital for Joint Diseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospital for Joint Diseases filed Critical Hospital for Joint Diseases
Publication of EP0550516A1 publication Critical patent/EP0550516A1/en
Publication of EP0550516A4 publication Critical patent/EP0550516A4/xx
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP91916608A 1990-09-28 1991-08-26 Method for inhibiting the infectivity of human immunodeficiency virus Withdrawn EP0550516A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58972290A 1990-09-28 1990-09-28
US589722 1990-09-28

Publications (2)

Publication Number Publication Date
EP0550516A1 EP0550516A1 (en) 1993-07-14
EP0550516A4 true EP0550516A4 (en) 1994-04-06

Family

ID=24359218

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91916608A Withdrawn EP0550516A1 (en) 1990-09-28 1991-08-26 Method for inhibiting the infectivity of human immunodeficiency virus

Country Status (4)

Country Link
EP (1) EP0550516A1 (en)
AU (1) AU653366B2 (en)
CA (1) CA2091253A1 (en)
WO (1) WO1992005799A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69227112D1 (en) * 1991-07-16 1998-10-29 Transmed Biotech Inc METHOD AND COMPOSITIONS FOR SIMULTANEOUS ANALYSIS OF A VARIETY OF ANALYZES
CA2152915A1 (en) * 1992-12-31 1994-07-21 Jonathan M. Gershoni Antibodies directed against binding-associated epitopes
DK0699077T3 (en) * 1993-05-07 2002-01-21 Bio Merieux Inc Immunogelous HIV complexes
CA2195238A1 (en) * 1994-07-19 1996-02-01 Robin Bachelder Antibodies that bind a conformationally altered cd4 molecule induced upon human immunodefficiency virus binding
EP0903860A1 (en) 1997-09-17 1999-03-24 Matsushita Electric Industrial Co., Ltd. PLL frequency synthesizer
ES2299276T3 (en) 1998-12-31 2008-05-16 Novartis Vaccines And Diagnostics, Inc. MODIFIED HIV ENV POLIPEPTIDES.
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
PT1137786E (en) * 1999-10-08 2007-07-13 Univ Maryland Biotech Inst Virus coat protein/receptor chimeras and methods of use
US6908612B2 (en) 1999-10-08 2005-06-21 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
US7311920B1 (en) 1999-10-08 2007-12-25 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
FR2799974B1 (en) * 1999-10-25 2001-11-30 Aventis Pasteur DEGLYCOSYL PROTEIN ENV / CD4 COMPLEX AND USE THEREOF FOR VACCINATION AGAINST HIV
CA2634992C (en) 2001-07-05 2012-10-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0226513A1 (en) * 1985-12-06 1987-06-24 Institut Pasteur Peptides capable of inhibiting interactions between antigens and lymphocytes T4, products derived therefrom and their applications
WO1988009181A2 (en) * 1987-05-29 1988-12-01 Tanox Biosystems, Inc. Monoclonal antibodies neutralizing hiv-1
US4908203A (en) * 1987-09-09 1990-03-13 Johnson & Johnson Method for inducing HIV neutralizing antibodies using an internal image idiotope

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0226513A1 (en) * 1985-12-06 1987-06-24 Institut Pasteur Peptides capable of inhibiting interactions between antigens and lymphocytes T4, products derived therefrom and their applications
WO1988009181A2 (en) * 1987-05-29 1988-12-01 Tanox Biosystems, Inc. Monoclonal antibodies neutralizing hiv-1
US4908203A (en) * 1987-09-09 1990-03-13 Johnson & Johnson Method for inducing HIV neutralizing antibodies using an internal image idiotope

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CELADA ET AL: "ANTIBODY RAISED AGAINST SOUBLE CD4-RGP120 COMPLEX RECOGNIZES THE CD4 MOIETY AND BLOCKS MEMBRANE FUSION WITHOUT INHIBITING CD4-GP120 BINDING", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 172, October 1990 (1990-10-01), NEW YORK,USA, pages 1143 - 1150 *
LINSLEY ET AL: "EFFECTS OF ANTI-GP120 MONOCLONAL ANTIBODIES ON CD4 RECEPTOR BINDING BY THE ENV PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1", JOURNAL OF VIROLOGY, vol. 62, no. 10, 1988, BALTIMORE,USA, pages 3695 - 3702, XP000579292 *
See also references of WO9205799A1 *
SKINNER ET AL: "NEUTRALIZING ANTIBODIES TO AN IMMUNODOMINANT ENVELOPE SEQUENCE DO NOT PREVENT GP120 BINDING TO CD4", JOURNAL OF VIROLOGY, vol. 62, no. 11, 1988, BALTIMORE,USA, pages 4195 - 4200 *

Also Published As

Publication number Publication date
AU653366B2 (en) 1994-09-29
EP0550516A1 (en) 1993-07-14
CA2091253A1 (en) 1992-03-29
AU8631791A (en) 1992-04-28
WO1992005799A1 (en) 1992-04-16

Similar Documents

Publication Publication Date Title
FR2659604B1 (en)
FR2658488B1 (en)
DK0493553T3 (en)
DE4193093T (en)
FR2660493B1 (en)
DE4193285T (en)
FR2657420B1 (en)
FR2659642B1 (en)
FR2657438B1 (en)
FR2657802B1 (en)
DE4190411T1 (en)
FR2659741B1 (en)
DE4190623T (en)
FR2662771B1 (en)
FR2662332B1 (en)
DE4190534T (en)
DE4192568T (en)
DE4191212T (en)
DE4190938T (en)
FR2670001B1 (en)
DE4191689T (en)
FR2657537B1 (en)
ECSM90484U (en)
ECSM90434U (en)
ECSM90421U (en)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930326

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

RHK1 Main classification (correction)

Ipc: C12P 21/08

A4 Supplementary search report drawn up and despatched

Effective date: 19940215

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19950831

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960301